Login to Your Account

No biting the hands that heal them: Animal health industry howls

By Marie Powers
Staff Writer

Monday, July 21, 2014

Petisation. You might be tempted to call it revenge of the lab rats. But the technology developed by Australian animal health company Nexvet Biopharma to adapt monoclonal antibodies (MAbs) developed for humans for use in animals – maintaining efficacy at the proper dose without risk of rejection – takes the lucrative animal health business to the next level.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription